- $740.09m
- $526.81m
- $2.98m
Annual balance sheet for Prime Medicine, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | PROSPECTUS | PROSPECTUS | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Cash and Equivalents | |||||
| Short Term Investments | |||||
| Cash and Short Term Investments | 53.3 | 270 | 294 | 122 | 190 |
| Prepaid Expenses | |||||
| Total Other Current Assets | |||||
| Total Current Assets | 53.4 | 271 | 297 | 143 | 212 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 0.596 | 15.7 | 48.6 | 36.6 | 71.6 |
| Other Long Term Assets | |||||
| Total Assets | 54.8 | 302 | 360 | 194 | 298 |
| Accounts Payable | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 19.4 | 58 | 26.7 | 56.4 | 38 |
| Total Long Term Debt | |||||
| Total Debt | |||||
| Deferred Income Tax | |||||
| Total Other Liabilities | |||||
| Total Liabilities | 21.3 | 62.3 | 44 | 60.8 | 144 |
| Redeemable Preferred Stock | |||||
| Non Redeemable Preferred Stock | |||||
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Unrealized Gain / Loss | |||||
| Total Equity | 33.5 | 240 | 316 | 133 | 153 |
| Total Liabilities & Shareholders' Equity | 54.8 | 302 | 360 | 194 | 298 |
| Total Common Shares Outstanding |